Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

49.87 -1.21 (-2.37%)
Official Closing Price Updated: 7:00 PM EDT, Aug 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 16,177,830
Open 50.40
Bid (Size) 49.93 (34)
Ask (Size) 50.00 (1)
Prev. Close 51.08
Today's Range 49.79 - 50.70
52wk Range 45.05 - 139.74
Shares Outstanding N/A
Dividend Yield 4.41%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Is the Market Bullish or Bearish on Novo Nordisk?
 
Via Benzinga
Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts
A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict 340B drug discounts for safety-net clinics, sending the case back to... 
Via Benzinga
Topics Lawsuit

Performance

YTD
-43.0%
-43.0%
1 Month
-27.7%
-27.7%
3 Month
-26.4%
-26.4%
6 Month
-40.6%
-40.6%
1 Year
-61.6%
-61.6%

More News

Read More
Deadline Alert: Novo Nordisk A/S (NVO) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
From Glancy Prongay & Murray LLP
Via Business Wire
Shareholders That lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO
Via NewMediaWire
Topics Fraud Lawsuit
4 of the Most Undervalued Stocks in the Market Right Now
Via The Motley Fool
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S (NYSE: NVO)
From Bernstein Liebhard LLP
Via GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
From The Rosen Law Firm PA
Via GlobeNewswire
2 High-Yield Dividend Stocks You Can Buy With $100 Now and Hold at Least a Decade
Via The Motley Fool
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
From Pomerantz LLP
Via GlobeNewswire
Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli Lilly
Via MarketBeat
Topics Government World Trade
MarketBeat Week in Review – 08/04 - 08/08
Via MarketBeat
Topics ETFs Economy World Trade
Why Hims & Hers Stock Sank This Week
Via The Motley Fool
Topics Lawsuit
Why Novo Nordisk Stock Flew Higher on Friday
Via The Motley Fool
Deadline Approaching: Novo Nordisk A/S (NVO) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
From Law Offices of Howard G. Smith
Via Business Wire
Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?
Via MarketBeat
Investors Who Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
Investors Who Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO
Via NewMediaWire
Topics Fraud Lawsuit
Novo Nordisk Stock Investors Need to Know This
Via The Motley Fool
Novo Nordisk Is Down 70%: Is the Price Too Low To Ignore?
Via The Motley Fool
Novo Nordisk Stock Climbs Over 4% In Friday Pre-Market: What's Going On?
Via Benzinga
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO): A Top Pick for Affordable Growth Investors
Via Chartmill
2 Brilliant Vanguard Index Funds to Buy With $1,000 in August and Hold Forever
Via The Motley Fool
Topics ETFs
Eli Lilly Stock Marks Worst Day In 25 Years As Weight-Loss Pill Data Disappoints: Analysts Divided But Retail Bets On Rebound
Via Stocktwits
NOVO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S and Encourages Investors to Contact the Fir
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
From The Rosen Law Firm PA
Via GlobeNewswire

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 49.87
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 08/11/25 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.